BillionToOne, Inc. (BLLN) stock: key figures, P/E, revenue and dividend

BillionToOne, Inc. financials

About BillionToOne, Inc.

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

More stocks

• HgCapital Trust PLC (HGT.L)
• Robotis Co.Ltd (108490.KQ)
• Great Microwave Technology Co. Ltd. A (688270.SS)
• GN Store Nord A/S (GN.CO)
• Sunstone Hotel Investors, Inc. (SHO)
• Verallia SA (VRLA.PA)
• Metalurgica Gerdau S.A (GOAU3.SA)
• Cal-Comp Electronics (Thailand) Public Company Limited (CCET.BK)
• RECURSION PHARMACEUTICALS, INC. (RXRX)
• Oesterreichische Post AG (POST.VI)
• Jiayou International Logistics Co Ltd (603871.SS)
• Beijing Haohua Energy Resource Co Ltd (601101.SS)